Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.28 +0.30 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
31 32 Next >
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
3 Healthcare Dividend Payers With Big Price Growth
Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers. 
Via MarketBeat
AbbVie Stock Shows Improved Relative Price Strength
AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see. 
Via Investor's Business Daily
Is Sanofi Stock a Buy Now?
The pharma giant has outperformed the broader market over the past 12 months. 
Via The Motley Fool
Looking Into Sanofi's Recent Short Interest
Via Benzinga
Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action
Via Investor Brand Network
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies... 
Via Benzinga
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information
Via Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... 
Via Benzinga
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens
Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday 
Via Investor's Business Daily
2 Top Healthcare Stocks Defying the Bear Market
The market sell-off over the past year hasn't stopped these healthcare giants from rallying. 
Via The Motley Fool
Why Shares of Regeneron Are Rising Thursday
Regeneron released positive phase 3 trial results for its therapy Dupixent. 
Via The Motley Fool
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
The companies' Dupixent reduced exacerbations by 30%. 
Via Investor's Business Daily
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years. 
Via The Motley Fool
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for. 
Via Investor's Business Daily
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication. 
Via The Motley Fool
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
The major indexes showed volatile, divergent action. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met... 
Via Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial... 
Via Benzinga
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
Bloomberg 
Via Benzinga
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. 
Via Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Reuters 
Via Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
Via Benzinga
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.